Across TCGA pan-cancer cohorts, CYHR1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CYHR1 data layer compared with 22 for mass-spec protein and 8 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CYHR1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CYHR1 expression acts as an unfavorable survival marker.

STAD, LUSC, and UCEC are the cancer types where CYHR1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.226	0.689	.002	24	view →
LUSC	OS	Median	All	0.304	0.677	.019	21	view →
UCEC	OS	Median	IV	0.133	0.754	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: CYHR1 tumor-vs-normal RNA expression · all CYHR1 data types